Altamira Therapeutics Announces Closing of up to $12.0 Million Public OfferingGlobeNewsWire • Thursday
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public OfferingGlobeNewsWire • Tuesday
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11GlobeNewsWire • 09/03/24
REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)GlobeNewsWire • 08/26/24
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and DenmarkGlobeNewsWire • 08/23/24
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited SubstancesGlobeNewsWire • 08/16/24
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor ModelsGlobeNewsWire • 08/12/24
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore NanoparticlesGlobeNewsWire • 07/19/24
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo ManagementGlobeNewsWire • 06/20/24
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalGlobeNewsWire • 05/23/24
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationGlobeNewsWire • 05/01/24
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalGlobeNewsWire • 04/24/24
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024GlobeNewsWire • 04/04/24
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesGlobeNewsWire • 03/25/24
Altamira Therapeutics' Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalGlobeNewsWire • 02/07/24
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentGlobeNewsWire • 01/24/24
Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitGlobeNewsWire • 01/08/24
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 12/29/23
Altamira Therapeutics to Host Investor & Business Update Call on December 11thGlobeNewsWire • 12/05/23
These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.Market Watch • 11/30/23
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementGlobeNewsWire • 11/29/23